FDA Approves Rasonque for Metastatic Pancreatic Cancer After Trial Doubled Survival to 13.2 Months
Updated
Updated · Healthcare Brew · Sep 8
FDA Approves Rasonque for Metastatic Pancreatic Cancer After Trial Doubled Survival to 13.2 Months
3 articles · Updated · Healthcare Brew · Sep 8
Summary
Aug. 26 approval cleared Revolution Medicines’ once-daily daraxonrasib for metastatic pancreatic adenocarcinoma in patients previously treated with chemotherapy.
Phase 3 data at 59 sites in six countries showed median overall survival of 13.2 months versus 6.7 months on standard chemotherapy, while doctors said patients also saw better quality of life.
Rasonque is the first approved treatment to target KRAS-driven disease in pancreatic cancer, a long-frustrating goal in a cancer with a 13% five-year survival rate.
Access may prove difficult: the drug carries a $39,800 monthly list price before insurance, versus about $5,501 a month for the commonly used FOLFIRINOX regimen.
Studies are already testing daraxonrasib earlier in treatment, in combination with chemotherapy, and in other RAS-mutated cancers; about 90% of pancreatic cancer patients carry a RAS mutation.
A breakthrough pill doubles pancreatic cancer survival, but at $477,000 a year, who will actually be able to afford it?
Could this once-daily pill targeting an undruggable mutation finally unlock the secret to surviving other deadly tumors?
It replaces harsh IV chemo, but do severe toxicities and hidden GI risks secretly compromise this new cancer pill's promise?
Rasonque’s 2026 FDA Approval: Doubling Survival in Pancreatic Cancer and Launching a New Era of RAS Inhibition
Overview
In August 2026, the FDA approved Rasonque (daraxonrasib) for metastatic pancreatic cancer, following impressive Phase 3 trial results that nearly doubled patient survival compared to chemotherapy. This oral targeted therapy, developed by Revolution Medicines, uses a unique tricomplex mechanism to block RAS proteins across many genotypes, offering a more tolerable alternative to traditional chemotherapy. The approval quickly changed cancer care, but its high price raised insurance and access challenges. As Rasonque moves into earlier treatment lines and new cancer types, genetic profiling will become essential, driving a shift toward more personalized and effective cancer therapies.